LONDON, October 15, 2012 /PRNewswire/ --
Silence Therapeutics plc has appointed Tim Freeborn, 53, as its finance director. A
chartered accountant, he joined the company from Xcap Securities
where he was head of research.
Tim Freeborn said: 'Silence's
area of biotech is moving incredibly quickly. The company could
play a big role and I'm delighted to be joining at this time.'
No further disclosures are required under Rule 17 and Schedule
2(g) of the AIM Rules.
Notes for editors
About Silence Therapeutics plc
(http://www.silence-therapeutics.com)
Silence Therapeutics plc (AIM: SLN) is a leading biotechnology
company dedicated to the discovery, development and delivery of
targeted, systemic RNA interference (RNAi) therapeutics for the
treatment of serious diseases. Silence offers one of the most
comprehensive short interfering RNA (siRNA) therapeutic platforms
available today based on a strong intellectual property portfolio
and large clinical safety database. Silence's clinical siRNA
product pipeline is one of the broadest in the industry. The
Company possesses multiple proprietary siRNA delivery technology
platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the
broad functional delivery of siRNA molecules to targeted diseased
tissues and cells, while increasing their bioavailability and
intracellular uptake. The DACC delivery system allows functional
delivery of siRNA molecules selectively to the lung endothelium
with a long duration of target mRNA and protein knock-down. The
DBTC delivery system enables functional delivery of siRNA molecules
selectively to liver cells including hepatocytes. Additionally, the
Company has a platform of novel siRNA molecules based around its
AtuRNAi chemical modification technology, which provides a number
of advantages over conventional siRNA molecules. Silence's unique
RNAi assets also include structural features for RNAi molecules and
specific design rules for increased potency and reduced off-target
effects of siRNA sequences.
The Company's lead internal drug candidate is Atu027, a
liposomal formulation in clinical development for systemic cancer
indications and one of the most clinically advanced RNAi
therapeutic candidates in the area of oncology. Atu027 incorporates
two of the Company's technologies, AtuRNAi and
AtuPLEX™.
The Company's RNAi therapeutic platform has received key
validation through multiple partnerships with pharmaceutical
companies including AstraZeneca, Dainippon Sumitomo, Pfizer/Quark,
and Novartis/Quark. Silence is actively pursuing the establishment
of additional partnerships. Silence Therapeutics has operations in
both Berlin and London.
Silence Therapeutics
Ali Mortazavi (+44-7768-694739
/Tim Freeborn (+44-20-7491-6520)
Email: a.mortazavi@silence-therapeutics.com
t.freeborn@silence-therapeutics.com
Singer Capital Markets
Shaun Dobson/Jenny Wyllie
+44-20-32057500
shaun.dobson@nplus1singer.com
jenny.wyllie@nplus1singer.com
M:Communications
Mary-Jane Elliot / Sarah MacLeod /
Claire Dickinson
+44-20-7920-2342
silencetherapeutics@mcomgroup.com
SOURCE Silence Therapeutics Plc